Insider Selling: Lexeo Therapeutics (NASDAQ:LXEO) COO Sells $20,903.68 in Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) COO Jose Manuel Otero sold 4,666 shares of the stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $4.48, for a total value of $20,903.68. Following the completion of the sale, the chief operating officer owned 137,482 shares of the company’s stock, valued at approximately $615,919.36. This represents a 3.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jose Manuel Otero also recently made the following trade(s):

• On Monday, May 18th, Jose Manuel Otero sold 1,302 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $5.07, for a total transaction of $6,601.14.

Lexeo Therapeutics Stock Performance

Shares of NASDAQ LXEO opened at $4.69 on Friday. Lexeo Therapeutics, Inc. has a 1 year low of $3.60 and a 1 year high of $10.99. The firm has a market cap of $368.26 million, a price-to-earnings ratio of -3.23 and a beta of 1.42. The stock’s 50-day simple moving average is $5.06 and its 200-day simple moving average is $6.58.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.04. As a group, research analysts predict that Lexeo Therapeutics, Inc. will post -1.21 EPS for the current year.

Institutional Investors Weigh In On Lexeo Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of LXEO. Allworth Financial LP increased its position in shares of Lexeo Therapeutics by 1,002.9% in the fourth quarter. Allworth Financial LP now owns 3,386 shares of the company’s stock worth $34,000 after acquiring an additional 3,079 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Lexeo Therapeutics by 69.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock valued at $35,000 after acquiring an additional 1,459 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Lexeo Therapeutics in the 4th quarter valued at approximately $37,000. California State Teachers Retirement System lifted its position in shares of Lexeo Therapeutics by 123.7% in the 4th quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock valued at $39,000 after acquiring an additional 2,148 shares in the last quarter. Finally, Cerity Partners LLC purchased a new stake in shares of Lexeo Therapeutics in the 2nd quarter valued at approximately $50,000. 60.67% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently weighed in on LXEO shares. Chardan Capital reiterated a “buy” rating and issued a $17.00 price objective on shares of Lexeo Therapeutics in a research report on Monday, May 11th. Wall Street Zen upgraded shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. JPMorgan Chase & Co. dropped their price target on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating on the stock in a research note on Thursday, June 25th. Finally, Weiss Ratings cut Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 25th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $18.75.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.